| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Abametapir (USAN/INN); Xeglyze (TN) | ||||||
| Product | XEGLYZE (Dr. Reddy's Laboratories) | ||||||
| Formula | C12H12N2 | ||||||
| Exact mass | 184.1 | ||||||
| Mol weight | 184.2371 | ||||||
| Structure |  | ||||||
| Class | Metabolizing enzyme substrate DG01892 CYP1A2 substrate | ||||||
| Remark |
| ||||||
| Efficacy | Pediculicide, Metalloproteinase inhibitor | ||||||
| Disease | Head lice infestation [DS:H01054] | ||||||
| Comment | Treatment of head lice | ||||||
| Metabolism | Enzyme: CYP1A2 [HSA:1544] | ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS P03A ECTOPARASITICIDES, INCL. SCABICIDES P03AX Other ectoparasiticides, incl. scabicides P03AX07 Abametapir D10687 Abametapir (USAN/INN) <US> USP drug classification [BR:br08302] Dermatological Agents Pediculicides/Scabicides Abametapir D10687 Abametapir (USAN/INN) Drug groups [BR:br08330] Metabolizing enzyme substrate DG01892 CYP1A2 substrate D10687 Abametapir New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10687 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10687 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D10687 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 14 1 C8x C 14.3562 -14.1450 2 C8x C 12.9562 -14.1367 3 C8y C 12.2491 -15.3450 4 C8x C 12.9419 -16.5615 5 N5x N 14.3419 -16.5698 6 C8y C 15.0490 -15.3615 7 C1a C 10.8491 -15.3450 8 C8y C 16.4490 -15.3615 9 N5x N 17.1358 -16.5505 10 C8x C 18.5358 -16.5502 11 C8y C 19.2355 -15.3376 12 C8x C 18.5487 -14.1486 13 C8x C 17.1487 -14.1489 14 C1a C 20.6355 -15.3376 BOND 15 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 3 7 1 8 6 8 1 9 8 9 2 10 9 10 1 11 10 11 2 12 11 12 1 13 12 13 2 14 8 13 1 15 11 14 1 |